Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70313 ↗At a glance
Übersichtsarbeit in Clinical Transplantation, 2025. Written by Dongdong Yu and 3 co-authors. Institution: Department of Orthopedic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Transplantation, Immunotherapy. Cited 1 times so far (Crossref); 195 references. Funded by: Zhejiang Provincial Natural Science Foundation of China, Medical Health Science and Technology Project of Zhejiang Provincial Health Commission.
Abstract (original language)
Immunocytotherapy has emerged as a promising therapeutic tool against hepatocellular carcinoma (HCC). Liver transplantation (LT) remains the primary option for curing HCC; however, post‐transplant tumor recurrence and the development of new malignancies significantly impact patient prognosis. The application of immune cell therapy in LT for HCC may reestablish antitumor immunity following transplantation without increasing the risk of rejection. In this review, we provide a concise overview of the suppressive tumor‐immune status and its impact on tumor recurrence and the development of neoplastic tumors after LT for HCC. We also examine the latest cellular cancer immunotherapy regimens for solid tumors, with a particular focus on HCC, and discuss their limitations. Finally, we summarize the challenges of applying cellular cancer immunotherapy in LT, including the potential induction of acute rejection and the suppressive effects of immunosuppressive agents, as well as potential coping strategies. In conclusion, cellular cancer immunotherapy may offer a potentially effective treatment for tumor recurrence in LT for HCC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Orthopedic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, China.
- Department of Lung Transplantation and Thoracic Surgery, First Affiliated Hospital, University School of Medicine, Hangzhou, Zhejiang, China.
- The Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, P.R. China.
ORCID profiles: Dongdong Yu
Funding
- Zhejiang Provincial Natural Science Foundation of China
- Medical Health Science and Technology Project of Zhejiang Provincial Health Commission
Cite
APA
Yu, D., Li, S., Chen, H., & Wang, L. (2025). Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade. Clinical Transplantation. https://doi.org/10.1111/ctr.70313
Vancouver
Yu D, Li S, Chen H, Wang L. Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade. Clinical Transplantation. 2025. doi:10.1111/ctr.70313
BibTeX
@article{Yu2025,
author = {Yu, Dongdong and Li, Shuchan and Chen, Hao and Wang, Lidong},
title = {Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70313}
}
EUVIMED